Orion Biotechnology

Orion Biotechnology is focused on discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapies to treat metabolic and immunological diseases. The company employs a novel drug modality that involves precision engineering of ligands for small protein GPCRs. Orion Biotechnology is supported by one of the fastest drug discovery platforms in the industry, known as PROcisionXᵀᴹ, which integrates streamlined phage display, multiplex chemical synthesis, structure-activity matrix, and refinement and optimization. This platform enables the rapid generation of first-in-class and best-in-class leads against peptide and protein GPCRs, producing optimized leads within 12 months. The company’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-class potency and has broad applicability across a range of serious diseases, including cancer, infectious disease, and neuroinflammatory disorders. Orion Biotechnology has completed the discovery of a first-in-class molecule against the undrugged GPCR target CXCR6 in four months, which has the potential to provide a new form of immunotherapy treatment for solid tumor cancers. The company’s pipeline also includes next-generation GPCR-targeted therapeutics for obesity and metabolic disorders, with OB-003 targeting CCR9 in the lead optimization phase for oncology and IBD, and OB-004 targeting CCR2 in the proof-of-concept phase for oncology and inflammation. Orion Biotechnology is headquartered in Ottawa, Canada, with locations in Switzerland and Poland. The Polish subsidiary is performing research and development under the Operational Programme – Smart Growth 2014-2020, with projects including the development of a new candidate microbicide for the prevention of HIV transmission and CCR5 immunotherapy for advanced cancer.